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Topical photodynamic therapy (PDT) is widely used to effectively treat superficial non-
melanoma skin cancer and dysplasia. As with any therapeutic approach, the risk/benefit profile 
must be taken into account on an individual patient basis; in general, PDT is well tolerated. 
Historically, PDT-induced pain has been a potentially limiting factor, but with optimisation of 
treatment parameters, such as the introduction of lower irradiance regimens, pain is now 
uncommonly a major issue. Expected “adverse” effects of a phototoxic insult also include 
inflammation, manifest as erythema, exudation and sometimes urticaria. Other side-effects are 
uncommon and include scarring, altered hair growth or pigmentary change and allergic 
reactions. The theoretical risk of carcinogenesis with cumulative PDT treatments is unproven 
and indeed PDT can be considered as a prophylactic approach in high-risk patients, such as the 
immunosuppressed. This review summarises the current evidence relating to the adverse 
effects of topical PDT as part of the guideline updating project on this subject1 and attempts to 
interpret this evidence in the context of patient risk (Table 1).  
 
1.1 Pain 
1.1.1 Characteristics and frequency 
PDT exerts its effects through a phototoxic mechanism, and as part of this, pain and 
inflammation occur. With some of the more conventional higher irradiance topical PDT 
regimens, pain during irradiation is almost invariable. The mechanisms of PDT-induced pain are 
poorly understood but studies in an adenocarcinoma cell line in vitro demonstrated preferential 
uptake of 5-aminolevulinic acid (ALA) by beta-amino acid and GABA transporters, which was 
not seen with methyl aminolevulinate (MAL); this may be one possible explanation for the 
neurogenic nature of the pain experienced during ALA-PDT, although this was in a cell line 
model and has not been substantiated in humans.2 In contrast, MAL uptake has been shown, in 
a human colon adenocarcinoma cell line, to be mediated by active transport mechanisms 
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involving non-polar amino acids, providing a potential rationale for any differences in pain 
mechanisms and experience during PDT following photosensitisation by either ALA or MAL.3  
 
Whilst there have been only limited studies of the mechanisms of PDT in human skin, it is clear 
that there is oxidative stress and generation of reactive oxygen species, and an inflammatory 
reaction involving release of histamine, nitric oxide, prostaglandin PGE2, TNF-alpha and other 
cytokines, and these may also be implicated in the pain and discomfort during and following 
PDT.2,4-6 In addition, a neurogenic mechanism involving TRP receptors has been implicated.7-9 
A recent study also showed mechanistic differences between ALA and MAL, in that ALA-PDT 
appeared to induce pain via singlet oxygen-mediated lipid peroxidation, in turn triggering 
nociceptor activation via TRPV1 receptors in dorsal root ganglia in vitro. Furthermore, the 
TRPV1 inhibitor, menthol, reduced action potentials evoked by ALA-PDT in dorsal root ganglia 
and pain behaviour in a mouse model, although this was not the case with MAL-PDT.10  
 
In humans, PDT-induced pain commences almost immediately after irradiation starts. 
Commonly, patients describe a prickling, stinging, sharp burning sensation, most similar to that 
reported by patients with erythropoetic protoporphyria.11,12 There is large inter-individual 
variation in the degree and nature of PDT-induced pain experienced by patients, although 
approximately 16% to 20% will report severe pain with conventional PDT.13-16 The multifactorial 
nature of PDT-induced pain and relative limitations of effective treatment options are well 
described.17 In one study which looked retrospectively at experience related to almost 1000 
PDT treatments, 44% of patients required some form of pain-reducing intervention.18 Indeed, in 
two separate studies, one a survey of PDT services in Scotland and the other a prospective 
cohort study, of patients treated with PDT for superficial BCC, SCC in situ or AK, 28% to 38% of 
patients reported moderate to severe pain (score over 6 on a 0-10 numerical rating scale).19,20 
Most of these data are derived from conventional topical PDT regimens using hospital-based, 
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relatively higher irradiance light delivery. However, the PDT procedure is generally very well 
tolerated, with the pain in the majority of cases resolving once the irradiation period ends (7-9 
minutes with the most widely used red LED source) and this is reflected in patient preference for 
PDT over alternative treatments. Nevertheless, the potential for this degree of pain is not ideal 
for patient care, and thus, information on predictive factors and suitable methods of pain relief 
are required. 
 
1.1.2 Predictive factors of PDT-induced pain 
Patient, lesion and treatment site characteristics 
The literature relating to possible predictors of PDT-induced pain is complicated by the fact that 
many of the studies reported are retrospective and have multiple confounding factors. There are 
conflicting reports of an impact of gender and skin phototype but there is no clear pattern 
emerging to suggest a strong effect of age, sex or skin phototype on likelihood of severe pain 
experienced with topical PDT.13,18,20-24 More consistently, there is evidence to support PDT to 
larger treatment areas being associated with more pain;13,14,16,18,22,23,25 therefore, this has the 
potential to limit the size of field that can be treated with conventional PDT, although the 
increasing use of daylight PDT (dPDT) has been beneficial in this regard.26 Any possible 
influence of diagnosis and body site is not clear, again due to potential confounders as, for 
example, AK tend to affect larger areas and arise on the head and neck. However, reports of 
PDT used for AK when compared with BCC,27 acne,28,29 psoriasis30,31 and viral warts32,33 indicate 
that higher PDT-induced pain scores may be observed when treating these conditions. Thus, it 
is important to have an awareness of this to minimise any potential impact on treatment delivery 
and to ensure that patients are appropriately advised and managed.  
 
One study also indicated that there was an association between more severe pain and the 
degree of erythema in the pre-treated lesion.14 However, this association has not been found by 
Page 4 of 36British Journal of Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
5 
other investigators.21 Likewise, whilst Lindberg et al. reported that the second treatment was 
more painful than the first in 38 patients treated with PDT34 it has, again, not been confirmed by 
other investigators.16,21,35 The study of Sandberg et al. also showed that lesions that responded 
best to PDT were associated with more pain,14 and it may be intuitive to consider that the more 
photosensitiser uptake and the greater lesional fluorescence and subsequent phototoxic insult, 
might well lead to the best therapeutic outcome. However, this is not the case when treating AK 
on the dorsal hands with PDT, as increasing protoporphyrin IX (PpIX) accumulation does not 
improve efficacy of treatment but increases adverse effects.36 Sub-group analysis of the larger, 
multicentre, randomized controlled trials (RCTs) of efficacy of PDT, particularly in dysplasia and 
superficial NMSC, have not been undertaken to investigate whether there is an association 
between fluorescence,37 phototoxic inflammation and subsequent therapeutic outcome.37 
Certainly, there is some evidence in smaller studies of a correlation between the degree of 
fluorescence intensity and pain experienced during PDT, and this has been shown in acne 
vulgaris28,38 and in AK. In the latter study, the association with pain was shown between both the 
degree of PpIX fluorescence and the fluence rate of light delivery, and this is supported by other 
investigators.16 Furthermore, pain is not required for PDT efficacy as exemplified by dPDT, 
which is considered to be due to the lower irradiance of daylight and of low level of continuous 
photoactivation of PpIX.39 
 
The influence of prodrug on PDT-induced pain 
In a double-blind, RCT investigating forearm sites in healthy volunteers which had been tape-
stripped, pain was higher on sites exposed to ALA than MAL. In addition, ALA induced higher 
levels of fluorescence, and there was a greater decrease in fluorescence with irradiation.38 In a 
separate study, the same group compared the pain associated with MAL-PDT with ALA-PDT for 
acne and AK, and showed that the pain experienced was greater with more intense PpIX 
fluorescence and with a higher rate of light delivery.40 This greater level of PpIX accumulation 
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and fluorescence associated with ALA has consistently been reported, both in normal skin41,42 
and diseased skin.28 In addition to higher levels of phototoxicity occurring in normal skin 
following ALA-PDT compared with MAL-PDT, more prolonged hyperpigmentation may also 
occur with the former.43 However, when analysing studies in which MAL-PDT and ALA-PDT 
have been compared directly, usually there have been other variables, in particular the duration 
of application of the prodrugs.44,45 Indeed, two small studies comparing ALA-PDT and MAL-PDT 
when used for nodular BCC and acne with application for 3 hours in each, showed no 
differences in acute pain scores between the prodrugs,28,46 although there was greater pain 
associated with ALA-PDT at 24 hours post-treatment in the acne study.28 More recently, in a 
large, multicentre study compa ing ALA in nanocolloid emulsion (BF-200 ALA) with MAL-PDT, 
there was no significant difference in adverse effects seen between the prodrug treatment 
arms.47 Reduction of drug concentration and/or incubation time may also be considered for 
effective, less painful PDT, as may be employed for AK or acne.48-50 With the development of 
newer formulations of topical prodrugs and lower drug dose regimens, vigilance is required to 
ascertain whether any change in depth of effect and efficacy may also be associated with 
changes in pain experienced and tolerance of treatment.51-53  
 
The influence of light delivery on PDT-induced pain 
Most topical PDT is undertaken using LED light delivery. There are few studies in which laser 
light delivery has been compared with non-coherent broadband light sources, although the 
evidence from two studies, one of which was retrospective, indicated no significant difference in 
efficacy or adverse effects, which included pain.11,54 Certainly, in vitro and in vivo studies 
support the safety profile of LED light delivery.55,56 Čarija et al. undertook a within-patient, 
prospective, controlled study of LED-PDT with pulse dye laser-PDT in 15 patients with 62 BCC 
lesions.57 Whilst there were similar pain scores between the treatment arms, lower clearance 
rates were seen at 12 months with pulse dye laser-PDT.  
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In the large, multicentre study comparing BF-200 ALA- and MAL-PDT for AK,47 more adverse 
effects were observed in patients treated with a narrower spectrum LED source than in those 
treated with a broader spectrum, albeit without longer-term safety concerns.58 Investigators 
have shown that variable pulsing of light delivery may reduce the pain associated with MAL-
PDT for AK in a prospective, controlled study that also showed no loss of efficacy or change in 
patient satisfaction.59 Other variables of light delivery have been studied, including the use of 
filtering of infrared in one study of 80 subjects, which was associated with less pain than 
conventional LED PDT, without loss of efficacy.60  
 
Most dermatological PDT uses red light for delivery of depth of effect but the wavelengths 
included do impact on PDT-induced pain. In one AK study where green and red light PDT were 
compared, less pain was experienced using the former with no loss of efficacy in this superficial 
indication.61 However, a similar study comparing green and red light for SCC in situ showed loss 
of efficacy with green light and no significant difference in pain.62 Mikolajewska et al. undertook 
a study in ten healthy volunteers exposed to topical ALA and MAL for 24 hours and irradiation 
was undertaken using either violet laser light or red laser light.63 In this study, greater pain was 
experienced in association with red light and a more persistent erythema seen for ALA-PDT, 
although these differences were not seen in the sites treated with MAL-PDT. However, the 
results have not been followed up with investigations in diseased tissue and the relevance of 
this in the clinical setting is unclear. There does not seem to be a strong association between 
pain experienced during PDT and the total light dose used,64 and this is likely reflecting the fact 
that pain is maximally experienced in the first half of irradiation.64-66 Thus, simply reducing the 
total dose used is unlikely to impact significantly on the tolerance of treatment.  
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However, there is substantial evidence that lower irradiance light delivery during PDT, such as 
dPDT or reduced irradiance hospital or portable device light delivery, is at least as effective as 
conventional higher irradiance regimens.37,39,40,67-72 It seems that at lower irradiances, 
particularly <50 mW/cm2, less pain is experienced during PDT.7,39,40,67-69,73-76  
 
In particular, the use of dPDT has been compared with conventional PDT in large, within-
patient, multicentre studies, most recently in Europe and Australia involving patients with mild to 
moderate field change AK.77,78 An overall consensus indicates that dPDT to large areas of AK is 
extremely well-tolerated, with much lower pain scores than for conventional PDT, and that 
efficacy rates are similar.70 In addition, in support of the use of low irradiance PDT, preliminary 
data obtained from non-comparative, open studies of low irradiance portable ambulatory LED 
devices37,71,72 indicate that pain scores are also very low and efficacy at 1 year follow-up is 
high.79  
 
These are important developments for the use of PDT in situations where pain previously could 
have been a treatment-limiting factor. This now enables larger areas to be treated in a well-
tolerated and an almost painless, effective regimen with dPDT. Another alternative means of 
varying irradiance using conventional hospital-based LED devices is with use of an initially 
reduced irradiance at less than 50 mW/cm2, and thereafter, for the latter part of the regimen, to 
increase irradiance in order to deliver an overall effective light dose. This approach of increasing 
irradiance during PDT after an initial lower (<50mW/cm2) irradiance approach to light delivery 
may be associated with reduced pain scores and can be useful for example if treating genital or 
perineal sites.80 This was investigated in a retrospective, single-arm study of 14 patients treated 
with this two-step irradiance regimen for BCC and SCC in situ, showing high clearance 
rates.81,82 Fractionation of light has also been investigated as a means of improving efficacy of 
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PDT,83 although this has been shown to be at the expense of increased adverse effects, notably 
pain.  
 
Pain – how does PDT compare with other treatments?  
When looking at the outcome of severe pain which requires a break in treatment or use of local 
infiltration anaesthesia, PDT results in significantly higher pain scores compared with 
placebo.29,47,84,85 This is also the case for lower levels of more manageable pain. Furthermore, 
when comparing dPDT with conventional PDT, the former is significantly less painful, based on 
large, multicentre studies.39,70,73,77,78  
 
In the larger studies comparing the outcome of severe pain which requires a break in treatment 
or use of local infiltration anaesthesia, no significant differences were seen between 
cryotherapy, 5-fluorouracil or imiquimod,35,86-88 whereas less pain was experienced with surgical 
excision than with PDT, although this would be expected as local anaesthesia is used for the 
surgical procedure.89 Of note, the pain and discomfort of other topical treatments, such as 5-
fluorouracil or imiquimod, is not directly comparable with PDT; the former are associated with 
increasing discomfort and inflammation during the course of treatment, over several weeks, 
whereas the pain experienced by PDT is maximal in the first few minutes of treatment which 
then subsides rapidly.35,90 This is an acute, rather than a more chronic experience, probably 
indicating why patient satisfaction levels with PDT are high.91  
 
Thus, when MAL-PDT was compared with ingenol mebutate for treatment of multiple AKs on 
the face and scalp in within-patient, split-face studies, pain scores and cosmetic outcome were 
higher with PDT, but local skin reactions were more severe and persistent with ingenol 
mebutate; overall, patients preferred PDT.92,93 When dPDT was compared with ingenol 
mebutate in 27 subjects with AK in a within-patient study, pain scores were higher for ingenol 
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mebutate.94 Similar efficacy was reported between the two groups but increased tolerance for 
dPDT was documented in terms of reduced local skin reactions and pain, and preference for 
dPDT.94 
 
Furthermore, in a randomized, observer-blinded, within-patient comparison of patients with 
multiple AKs treated with trichloroacetic acid compared with ALA-PDT, higher pain scores and 
efficacy rates were seen with PDT and scarring was present only in those treated with 
trichloroacetic acid.95  
 
1.1.3 Pain relief for PDT-induced pain 
 
Treating with methods of no significant benefit 
Given the nature of PDT-induced pain and the probable neurogenic mechanisms involved, it 
may be anticipated that topical anaesthesia could be beneficial for pain relief during PDT. 
However, in a within-patient, double-blind RCT of ALA for extensive AK on the scalp, Langan et 
al. failed to show a significant effect of eutectic mixture of local anaesthetics (EMLA) for PDT-
induced pain.96 This is supported by observations by Grapengiesser et al. in 60 patients in 
which EMLA was used during PDT.13 A separate inter-individual study by Holmes et al. found no 
significant effect of tetracaine gel (Ametop®) used topically during ALA-PDT for superficial BCC, 
SCC in situ or AK.97 Likewise, during large-area PDT for facial AK and field change 
carcinogenesis, no benefit of topical 3% lidocaine hydrochloride cream was found.98 In a 
randomized, double-blind, placebo controlled study, morphine gel 0.3% was shown not to be 
significantly beneficial for pain relief during topical MAL-PDT;99 Sandberg et al. observed that 
capsaicin cream was also not significantly effective in reducing pain and there were side-effects 
of the topical capsaicin itself.14  
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Treating with methods of potential benefit 
In contrast, a pilot, open, split-face study performed by Borelli et al. on the use of subcutaneous 
infiltration of 1% ropivacaine with 1% prilocaine for PDT pain relief showed benefit, although 
there were significant adverse effects of cheek swelling persisting for up to 3 days, which could 
limit its use.100 This has been supported in a separate case report showing the benefit of 
subcutaneous anaesthesia for pain relief during PDT in a 7 year-old child.101 
 
In addition, peripheral nerve blockade can be significantly effective in reducing PDT-induced 
pain when used for extensive facial AK. In an initial study in 16 patients with symmetrical facial 
AK, nerve blockade using mepivacaine and adrenaline was used to block supra-orbital, supra-
trochlear, infra-orbital and mental nerves and the non-anesthetised side served as control. Pain 
scores were significantly reduced on the anaesthetised side and 15 of the 16 patients 
expressed preference for nerve blockade in future if PDT was required.102 This has also been 
supported by a separate study in 10 males with facial AK using supra-orbital, supra-trochlear 
and occipital nerve blockade during MAL-PDT.103 In an open clinical trial involving 34 patients 
with frontal facial AK where supra-orbital and supra-trochlear nerve blockade was used on one 
side and cold air analgesia on the other, nerve blockade was significantly superior with respect 
to pain relief, with preference in 31 of the 34 patients.104 However, nerve blockade is only 
possible at certain body sites, and of course, requires an additional invasive procedure, and as 
such, it may not be appropriate for many patients treated with PDT.  
 
In a prospective, controlled, observational study to address the potential effect of nitrous oxide, 
involving 71 patients treated with MAL-PDT to multiple AKs on the cheeks, all patients received 
800 mg of ibuprofen 30 minutes before PDT irradiation. In addition, cooling was used with a cold 
air fan and interruptions in treatment were allowed if required and, for patients who experienced 
severe pain (visual analogue scale, VAS, score of ≥ 6) despite ibuprofen and cooling air, 
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additional nitrous oxide and oxygen mixture (Livopan®) was offered for PDT to the other cheek. 
Overall, a reduction in pain score of 55.2% was seen between treatments to the first and second 
cheek following application of the nitrous oxide and oxygen mixture. Treatment was generally 
well-tolerated, although 6 of 30 patients (20%) experienced mild side-effects during inhalation of 
the nitrous oxide and oxygen mix, which included vertigo, fear of loss of control and 
amplification of noise.105 
 
Considering other options for pain relief during PDT, investigators have explored the potential 
use of transcutaneous electrical nerve stimulation (TENS). This was undertaken in a pilot study 
in 14 patients with facial and scalp AK who had experienced severe pain during earlier PDT 
treatments. When the TENS electrodes were placed on the shoulders, four patients found no 
benefit from the use of TENS, three patients (21%) who had had previous interrupted PDT 
sessions due to pain were able to complete treatment, although the reduction in pain scores 
was modest (8.1 – 6.2). Overall, all but one patient would have used TENS again during PDT. 
This pilot study requires further investigation, although TENS is only feasible at certain body 
sites and therefore may have limited application in routine clinical use.106  
 
In many PDT regimens, use of a cold-water spray is employed as a routine measure during 
PDT. In a double-blind, controlled study involving 85 patients treated with ALA-PDT for AK or 
acne vulgaris, two thermal spring waters were investigated and sprayed four times daily to the 
face for a week following PDT. A reduction in discomfort, pain and erythema was experienced 
between days two and seven, although no impact was shown on the period of maximal pain, 
which was on day one.107 In a separate study in 24 patients with AK treated with MAL-PDT on 
two symmetrical areas, cooling with either cold water spray or cold water pack was employed in 
either the first or second period of illumination. The water spray and cool pack reduced mean 
pain scores modestly by 1.2 - 1.3 points, however, pausing irradiation was associated with a 
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higher reduction in pain of 3 – 3.7 points. Thus, whilst cooling resulted in minor reduction in pain 
intensity, a pause in illumination was more effective for pain relief, and these are relatively easy 
ways that can be incorporated routinely into clinical PDT practice.108 Pausing during illumination 
may also be useful when treating acne with PDT.51 The relatively small impact of cooling air on 
reduced PDT-associated pain was also shown by Stangeland et al. who undertook an open, 
within-patient, right-left comparison study in 43 patients treated with MAL-PDT for field change 
cancerisation, showing a small but significant reduction in pain scores in those treated with cold 
air analgesia.109 These observations of the utility of cooling are supported by a non-randomized, 
retrospective, observational, controlled study in which cooling devices were seen to be 
associated with reduced PpIX photobleaching. However, a reduction in disease clearance rate 
was seen at 3 months of follow-up and thus cooling should be used with caution because of 
concerns about adverse impact on therapeutic effect.110  
 
Other treatment methods 
Less conventional approaches have included a plant-derived spray which contained camomile 
and menthol, which was used in addition to glycolic acid. A randomized, blinded study involving 
56 patients with field change cancerisation of either arm (n=25) or face (n=31) showed reduced 
pain scores at all time points up to 30 minutes, during and after treatment. The sprays were 
applied to treatment areas 10 minutes before irradiation and at any time during irradiation, with 
the placebo being a coffee scented saline spray.111 Whilst this may be a relatively simple 
method to reduce discomfort when large areas are treated with PDT, it needs further study. 
 
Whilst PDT is generally well tolerated, exploring options for patients who have found PDT to be 
painful is worthwhile. A single session of hypnosis was explored in a pilot study of 12 patients 
treated with PDT for pre-cancerous lesions (actinic keratosis, SCC in-situ, Bowenoid papulosis 
and Paget’s disease), showing significantly reduced pain scores in eight patients, six of whom 
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had previously experienced PDT without hypnosis. Whilst it would not be required for most 
patients treated with PDT, hypnosis requires further investigation as it could be considered in 
exceptional circumstances if proven to be effective. A limitation would be the requirement for 
members of staff to be trained adequately in hypnosis.112  
 
Thus, whilst nerve block, subcutaneous infiltration with anaesthetic, TENS, cooling air and/or 
pausing irradiation may be of benefit, more typical forms of topical anaesthetics or oral 
analgesics20,113 have not been shown to be effective. Modifying PDT regimens to employ lower 
irradiance light delivery is usually most effective, enabling successful treatment.7,114  
 
1.2 Phototoxicity of topical PDT 
The inflammatory reaction following PDT is expected as a consequence of the phototoxic effect. 
This usually manifests as erythema and oedema, and sometimes with associated wheal and 
flare, i.e. an urticarial reaction.115,116 Persistence of erythema may be seen for some months 
following treatment.11 Crusting, infection, sterile pustules and erosions are also uncommon 
adverse effects.117  
 
In a study involving ten healthy volunteers, erythema induced by ALA-PDT peaked at 1-2 hours 
following cessation of irradiation,6 although laser Doppler studies118 have shown that the 
increase in blood flow that occurs immediately after topical PDT persists for a week. Marked 
inter-individual variability is seen in phototoxic reaction and there are also body sites effects, 
with reports of increased phototoxic reactions mid-face,119 consistent with increased pain at this 
site.22 Phototoxic inflammation seems to be greater following the application of ALA rather than 
MAL. In a randomized comparison of ALA- and MAL-PDT involving 34 healthy volunteers, a 
composite score of erythema, oedema and pigmentation was significantly greater for ALA-PDT 
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than for MAL-PDT, which likely reflected the increased pigmentation seen with ALA-PDT, 
persisting for 4 weeks.43  
 
Detailed investigation of ALA-PDT-induced phototoxicity in normal human skin indicated the 
release of histamine, accompanying an early urticarial phase, although cetirizine showed no 
effect on the erythemal response at 24 hours.4 Consistent with this is the occurrence of clinically 
reported urticaria seen immediately, during and after topical PDT in a small proportion of 
patients, and possibly being more likely in those with severe photodamage. The incidence of 
urticaria has been reported to be between 0.9% – 3.8%, and antihistamines may be of some 
benefit when used prophylactically for itch and wheal.120,121 Prominent phototoxic erythema, 
associated with malaise and flu-like symptoms, was recently reported in two organ transplant 
recipients treated with PDT for photodamage.122 
 
Whilst there is significant evidence of an association between prodrug-induced fluorescence, 
phototoxicity and pain,21,40,123,124 an association between phototoxicity and therapeutic outcome 
is less clear-cut. An association between PpIX photobleaching and clinical outcome at 3 
months’ follow-up following PDT treatment was observed in a pilot study in diseased skin.125 In a 
separate study involving 24 healthy volunteers, forearm skin was tape-stripped and during 
different times of incubation of MAL, fluorescence photobleaching was assessed during red light 
irradiation. A significant correlation was seen between the incubation time of the prodrug and 
time to illumination and photobleaching; there was also a significant correlation between 
photobleaching and erythema, and between photobleaching and pain. These imply that shorter 
incubation periods of the prodrug may result in reduced pain, although impact on efficacy in 
diseased skin is unclear.126 In addition, reduced MAL concentration may also reduce any 
potential for increased pigmentation.127  
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In a study of 22 patients with field change mild AK on the face and scalp, the application of MAL 
for 30 minutes compared with MAL for 3 hours, with both sites then irradiated at 3 hours was 
investigated. The application of a super-potent corticosteroid before and after PDT to the short 
application, pulsed PDT site was also investigated. The reduction of MAL application time and 
the use of topical corticosteroid reduced PDT-induced erythema at 24 hours but did not impact 
on efficacy at 3 months.128 The same group studied 22 subjects with facial and scalp AK 
separately and also showed that application of a super-potent corticosteroid reduced the 
inflammation and erythema of PDT but did not impair efficacy.129 Furthermore, during dPDT, 
using light protection of the skin following PDT appears to reduce inflammation, although its 
impact on efficacy is unclear.130 It is also of interest to note that brimonidine tartrate gel may 
also have the potential to reduce erythema following dPDT, although its impact on efficacy, 
again, is unknown.131 
 
Patient satisfaction, tolerance and cosmetic outcome 
High levels of patient satisfaction are reported for PDT, although pain may impact on patients’ 
perception of the treatment.77,78,87,91,132-138 Improved tolerance and satisfaction with PDT was 
reported in one randomized study comparing PDT with imiquimod for AK139-141 and improved 
preference for PDT compared with cryotherapy was reported in a RCT comparing MAL-PDT 
with cryotherapy for superficial BCC with a 5-year follow-up.87 MAL-PDT compares favourably 
with ingenol mebutate when used for AKs on the face and scalp, with superior cosmetic 
outcomes and an overall patient preference for PDT, due to higher pain scores and local skin 
reactions being more severe and persistent with ingenol mebutate.92,93 Similarly, when dPDT 
was compared with ingenol mebutate in 27 subjects with AK in a within-patient study, the former 
was better tolerated and preferred, and was associated with fewer adverse effects; efficacy was 
similar between the two modalities.94 When comparing trichloroacetic acid with ALA-PDT for 
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scalp AK, higher efficacy rates and pain scores were seen with PDT and scarring was present 
only in the trichloroacetic acid-treated subjects.95  
 
1.3 Allergic contact dermatitis to prodrugs 
Topical PDT induces an inflammatory reaction consisting of erythema, often with some oedema 
and subsequent crusting; these are expected effects of topical PDT. The degree and severity 
often reflect the severity of photodamage and the area that is treated. Whilst it could be the 
development of an irritant dermatitis, the possibility of the patient becoming sensitised and 
having developed allergic contact dermatitis to the prodrug should be considered, especially 
with a prolonged and persistent inflammation following PDT. 
 
There are independent reports of allergic contact dermatitis arising to MAL.142-148 In one study, 
positive patch testing to MAL cream (but not to placebo) was seen, indicating that this is likely to 
be due to the prodrug itself and not the excipient.146 The risk of sensitisation is predicted to be of 
the order of 1-2%.145,146 However, it is important to be aware of this possible adverse effect as a 
more generalised dermatitis can occur if this is not recognised and PDT is continued.144,149 
Contact dermatitis has been reported to MAL and, more recently, to BF-200 ALA.148  
 
Reviewing the separate studies, the risk of sensitisation is increased in those patients who have 
had multiple treatments with PDT and large areas treated. It is important to be aware of and 
have a low threshold for considering patch testing in patients who develop a more severe or 
atypical reaction to PDT. With increasing use of dPDT for large-area treatment it would be wise 
to be vigilant in this patient group. 
 
1.4 Medium-term adverse effects 
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The relative selectivity of PDT and the observation from large, multicentre studies that healing 
and cosmetic outcome are good77,78,87,91,132-138 mean that PDT is often selected as the treatment 
of choice to use at difficult sites such as lower legs, where healing may be problematic. Whilst 
changes of fibrosis can be seen histologically following PDT,150 scarring is rarely 
reported77,78,87,91,132-138,151 and indeed PDT has been explored for its use in scar remodelling152 
and potential to treat keloid scar,153 although this requires further investigation. Rarely, milia 
cysts may occur following PDT if the basal membrane is disrupted; this may be difficult to 
distinguish from recurrent BCC154 but in practice this is an occasional adverse effect. 
 
In early studies of the use of high-intensity PDT regimens for acne vulgaris, biopsy evidence of 
destruction of sebaceous glands was observed,155 although current acne regimens are of lower 
intensity with regard to irradiation. As such, it is anticipated that the risk of permanent damage 
to sebaceous glands will be lowered, although further studies with histological evidence of this 
have not been undertaken. Sterile pustules are often reported following PDT for acne vulgaris, 
although true infection is rarely seen,28,29 probably because of the anti-infective effects of PDT. 
Photo-onycholysis is well recognised with drug phototoxicity such as with psoralens156 and there 
are isolated reports of photo-onycholysis occurring following PDT when this has been 
undertaken at periungual sites, such as for viral warts157 and AK,158 and even one case arising 
following blue light ALA-PDT to AK on the face.159 
 
Pigmentary problems  
Dyspigmentation may occur following PDT although is uncommon; in fact, in the larger trials 
involving AK, extramammary Paget’s disease, warts and acne, no significant pigmentary 
changes were detected.51,160-162 Hyperpigmentation43 may occur which seems particularly likely 
with darker skin phototypes, and has been seen in the context of using PDT for acne 
vulgaris.155,163 However, in light-skinned populations, hyperpigmentation is only rarely seen.151 It 
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is also not clear whether combining PDT with any pre-treatment steps may increase the risk of 
pigmentation. In one study, whilst there was a trend to increased pigmentation with CO2 laser-
assisted PDT, this was not significantly different from PDT alone.160  
 
If hyperpigmentation occurs, it is usually reversible over some weeks. In one study, biopsy of 
PDT-induced pigmentation showed histologically increased numbers of activated 
melanocytes.164 Hypopigmentation may also occur, presumably as a post-inflammatory insult, 
although is rarely a problem clinically.151 
 
Hair problems 
If PDT is undertaken at hair-bearing sites such as the scalp or beard area, there is potential for 
hair loss, and this has been observed following PDT treatment of large areas of SCC in situ and 
BCC.165 However, this is not well reported in the literature but may be worth keeping in mind 
with regard to warning patients of this potential side-effect at the relevant treatment sites. 
Paradoxically, topical PDT may also increase hair growth, and one of the early studies of topical 
PDT was using hematoporphyrin derivative and UVA irradiation as an attempt to treat areas of 
alopecia areata.166 Although that initial study was encouraging, subsequent studies have been 
disappointing, showing no convincing efficacy.167,168 However, one report of a study in mice 
indicated that the presence of iron was required with ALA to stimulate hair growth, although this 
has not been investigated in humans.169 
 
1.5 Miscellaneous 
Thus, whilst the main adverse effects of PDT are pain, which can usually be minimised through 
modification of treatment approaches and the expected inflammatory phototoxic reaction, there 
have been rare reports of other miscellaneous adverse effects. PDT has been used to treat 
erosive pustular dermatosis, but there are also reports of the development of erosive pustular 
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dermatosis of the scalp occurring within 1-3 months following PDT treatment of AK of the 
scalp;170,171 the possibility that this may be triggered by the insult of PDT exists. Possibly via 
similar mechanisms, localised bullous pemphigoid developing 3-4 months following PDT has 
also been observed.172,173 In the more recent study, the patient additionally developed blistering 
lesions at non-treatment sites,173 and in both cases, whilst it is possible to speculate that the 
trigger may have been PDT, it is not clear-cut and may have been coincidental. Likewise, a 
case of pemphigus vulgaris developing one week after a third PDT session at an adjacent site 
raises the possibility of an association, although again, it may have been coincidental as the 
condition generalised.174  
 
The antimicrobial effects of PDT are increasingly being explored and infection following PDT is 
unusual and less likely than with other topical therapies.88 Interestingly, despite a report of 
reactivation of herpes simplex virus at the treatment site, 24-48 hrs following PDT for AK on the 
forehead,175 topical ALA PDT has also been investigated in eight patients with recurrent herpes 
simplex virus infection (oral and genital), with encouraging preliminary data suggesting that PDT 
may have therapeutic and preventative effects in reduction of HSV recurrence and this warrants 
further study.176 There was one report of a peripheral nerve palsy developing 1 week following a 
second treatment session with MAL-PDT for facial AK (forehead, cheek and jaw).177 Other 
causes of facial palsy were excluded, and despite systemic corticosteroids, the patient had no 
clinical improvement in the facial palsy at 16-month follow-up. Whilst this may have been 
coincidental, the occurrence on the same side of treatment, just 1 week post-treatment, raises 
the possibility of causal association; this could be either due to a direct traumatic effect of PDT 
on the superficial facial nerve branches or through viral reactivation, although there was no 
evidence of this in this case. There were also four cases reported of cellulitis developing 
following treatment of AK with PDT.178 
 
Page 20 of 36British Journal of Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
21 
There was a report of five patients who developed transient memory impairment and global 
amnesia immediately following PDT for AK.179 This did not appear to be associated with pain, 
and the neurological symptoms all resolved without sequelae within 24 hours; the patients were 
investigated and no significant neurological or vascular disease was found. Three of the five 
patients had elevated blood pressure immediately post-treatment,179 and this has been 
documented in a separate report, including what was documented as hypertensive crisis in four 
patients after MAL-PDT. All had known hypertension and were on medication for this.180 This 
latter observation is of interest in that blood pressure measurements are not undertaken 
routinely before, during and after MAL-PDT, but perhaps monitoring of hypertensive patients 
should be considered.  Rarely systemic flu-like symptoms may occur, with a report of intense 
phototoxic reactions and systemic malaise in two immunosuppressed patients following PDT 
and this has not previously been reported, so perhaps we need to more actively enquire about 
this in patients who are severely photodamaged, possibly immunocompromised and receiving 
PDT to large areas.122  
 
1.6 Carcinogenesis 
Whilst in vitro PDT may have cytotoxic and genotoxic effects,181,182 the porphyrin-derived 
molecules used in topical PDT can also have both antioxidant and anti-mutagenic actions.183 In 
hairless mouse models, both MAL-PDT and hexylaminolevulinate (HAL)-PDT have separately 
been shown to delay the time to development of SCC, using repeated treatment regimens,184-187 
although caution is required in extrapolating these data to the human setting and indeed only 
marginal effects on delayed tumour development were seen with daylight PDT when using 
HAL.187 However, in a split-face study involving 25 renal transplant recipients, repeated topical 
PDT at 6-monthly intervals for 5 years delayed the development of AK, supporting an earlier 
randomised, within-patient study. In this earlier study involving 81 patients with AK treated with 
either MAL-PDT or lesion-specific therapy such as cryotherapy, the former significantly reduced 
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the development of new AK, although the effect was not maintained at longer-term follow-up 
over 2 years.188 Whilst PDT does not have the same mechanisms of action as ultraviolet 
radiation (for example, it does not activate p53, although upregulates p21),189 it is 
immunosuppressive.190,191 The immunosuppressive effects of PDT appear to be reduced by 
lowering the irradiance of light delivery, and by nicotinamide.192,193  
 
Unlike many cancer therapies, topical PDT is often repeated and there is no clear evidence of a 
cumulative toxic effect. However, there are observations of the development of eruptive 
keratoacanthomas following PDT,194-196 which may be in association with the trauma inflicted on 
the skin by PDT aggravating o  provoking the development of keratoacanthoma.197 There are 
reports of the development of invasive and sometimes poorly differentiated SCC arising within a 
few months of PDT treatment.198-200 There are also isolated reports of melanoma developing at 
the site of PDT201,202 and of a microcystic adnexal carcinoma developing at a site of SCC in situ 
treated by PDT several years earlier.203 However, given that the majority of these patients had 
pre-existing, extensive field change, with pre-cancerous and cancerous change, as well as a 
history of skin malignancies, association with PDT itself is very difficult to prove and these may 
well be coincidental cases. Likewise, the development of SCC arising after PDT for 
erythroplasia of Queyrat of the penis, as an isolated report,204 may also have been coincidental. 
A recent retrospective study assessing cases of invasive SCC arising in areas previously 
treated by topical MAL-PDT identified 10 SCC in 699 treated patients with no significant 
histological or immune-histochemical differences compared with SCC lesions developing in non-
PDT treated areas. The patients who developed SCC all had multiple AK or SCC in situ and 
hence were pre-disposed to invasive SCC development although an association with multiple 
(median 5 treatments over 1 year) PDT sessions is highlighted.205 However, vigilance is 
required, and reporting is to be encouraged. Whilst longer-term follow-up of patients receiving 
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PDT is ideal, it is often not practical as patients are often elderly and frail, and due to pressures 
on outpatient services.  
 
1.7 Safety aspects of topical PDT  
Contraindications to PDT include a history of porphyria and allergy/photoallergy to active 
ingredients of the applied photosensitizer.143,145,196 Most PDT is carried out using red light which 
is not phototoxic to the retina. However, blue light can pose a hazard to the retina, potentially 
causing irreversible damage to the photosensitive neurotransmitters in the macula.206 Wearing 
goggles, for both patient and staff, is recommended to limit the transmission of high-intensity 
light and to avoid discomfort and disturbance of colour perception. Following topical PDT, 
localized photosensitivity can remain for up to 48 h.124,207 
 
1.8 Conclusions 
In summary, topical PDT is a widely used and evaluated therapy, which is generally very well 
tolerated by most patients. Whilst pain and discomfort during irradiation are the main adverse 
effects during conventional PDT, adjustment of irradiation regimens, including the use of low 
irradiance options such as dPDT, generally ensures that PDT can be administered effectively 
and safely. Other expected skin phototoxicity effects, notably erythema and oedema, resolve 
rapidly over a few days and longer-term adverse effects, such as pigmentary change, scarring 
or contact allergy, are uncommon. Thus, PDT has an important place in the management 
options of patients with superficial non-melanoma skin cancer and dysplasia as highlighted in 
current guidelines.1 
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Table 1: The adverse effects of topical photodynamic therapy 
 
Adverse effect Prevalence 
Discomfort and/or pain  Common 
Erythema, oedema, exudation, crusting 
(phototoxicity)   
Common (expected) 
Sterile pustules Relatively common when 
treating acne 
Urticaria  Uncommon 
Infection (bacterial or viral)   Uncommon 
Purpura and/or bruising  Uncommon 
Scarring (hypertrophic or atrophic)  Uncommon 
Milia  Uncommon 
Photo-onycholysis  Uncommon 
Dyspigmentation (increased or decreased 
pigmentation)  
Uncommon 
Changes in hair growth (increase or loss)  Uncommon 
Dermatitis and contact allergy to pro-drug Uncommon 
Systemic features: hypertension, flu-like 
symptoms 
Rare and unproven 
Neurological symptoms: nerve palsy, 
transient amnesia  
Rare and unproven 
Skin cancer risk  No proven risk and may have 
preventative role 
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